Anna D'Agostino

Dr. Anna D'Agostino

IRCCS SYNLAB SDN, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GCGiulia Crisci
Giulia Crisci
MLMariarosaria De Luca
Mariarosaria De Luca
Roberta D'AssanteRoberta D'Assante
Roberta D'Assante
BRBrigida Ranieri
Brigida Ranieri
ADAnna D'Agostino
Anna D'Agostino
ASAndrea Salzano
Andrea Salzano
Heart failure with preserved ejection fraction (HFpEF) represents the most common HF phenotype of patients aged > 65 years, with an incidence and a prevalence that are constantly growing. The HFpEF cardinal symptom is exercise intolerance (EI), defined as the impaired ability to perform physical activity and to reach the predicted age-related level of exercise duration in the absence of symptoms—such as fatigue or dyspnea—and is associated with a poor quality of life, a higher number of hospitalizations, and poor outcomes. The evidence of the protective effect between exercise and adverse cardiovascular outcomes is numerous and long-established. Regular exercise is known to reduce cardiovascular events and overall mortality both in apparently healthy individuals and in patients with established cardiovascular disease, representing a cornerstone in the prevention and treatment of many cardio-metabolic conditions. Several studies have investigated the role of exercise in HFpEF patients. The present review aims to dwell upon the effects of exercise on HFpEF. For this purpose, the relevant data from a literature search (PubMed, EMBASE, and Medline) were reviewed. The analysis of these studies underlines the fact that exercise training programs improve the cardiorespiratory performance of HFpEF patients in terms of the increase in peak oxygen uptake, the 6 min walk test distance, and the ventilatory threshold; on the other hand, diastolic or systolic functions are generally unchanged or only partially modified by exercise, suggesting that multiple mechanisms contribute to the improvement of exercise tolerance in HFpEF patients. In conclusion, considering that exercise training programs are able to improve the cardiorespiratory performance of HFpEF patients, the prescription of exercise training programs should be encouraged in stable HFpEF patients, and further research is needed to better elucidate the pathophysiological mechanisms underpinning the beneficial effects described.

1 July 2021 in Heart Failure Clinics
Verified
Journal Article
Closed access
ASAndrea Salzano
Andrea Salzano
MLMariarosaria De Luca
Mariarosaria De Luca
MIMuhammad Zubair Israr
Muhammad Zubair Israr
GCGiulia Crisci
Giulia Crisci
MEMohamed Eltayeb
Mohamed Eltayeb
AMAlberto M. Marra
Alberto M. Marra

Verified
Journal Article
Open access
PDF file
Maria Rosaria RuoccoMaria Rosaria Ruocco
Maria Rosaria Ruocco
AGArmando Gisonna
Armando Gisonna
VAVittoria Acampora
Vittoria Acampora
ADAnna D'Agostino
Anna D'Agostino
BCBarbara Carrese
Barbara Carrese
Giuseppe FiumeGiuseppe Fiume
Giuseppe Fiume
Breast cancers (BCs) are solid tumors composed of heterogeneous tissues consisting of cancer cells and an ever-changing tumor microenvironment (TME). The TME includes, among other non-cancer cell types, immune cells influencing the immune context of cancer tissues. In particular, the cross talk of immune cells and their interactions with cancer cells dramatically influence BC dissemination, immunoediting, and the outcomes of cancer therapies. Tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) represent prominent immune cell populations of breast TMEs, and they have important roles in cancer immunoescape and dissemination. Therefore, in this article we review the features of TILs, TAMs, and MDSCs in BCs. Moreover, we highlight the mechanisms by which these immune cells remodel the immune TME and lead to breast cancer metastasis.

21 January 2022 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
LFLorenzo Falsetti
Lorenzo Falsetti
AMAlberto Maria Marra
Alberto Maria Marra
VZVincenzo Zaccone
Vincenzo Zaccone
MSMattia Sampaolesi
Mattia Sampaolesi
FRFrancesca Riccomi
Francesca Riccomi
ASAldo Salvi
Aldo Salvi

Verified
Journal Article
Open access
PDF file
CMCiro Mauro
Ciro Mauro
VCValentina Capone
Valentina Capone
RCRosangela Cocchia
Rosangela Cocchia
Filippo CademartiriFilippo Cademartiri
Filippo Cademartiri
FRFerdinando Riccardi
Ferdinando Riccardi
ASAndrea Salzano
Andrea Salzano
Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years, because of the possibility of early diagnosis and the increased efficacy of neo-adjuvant and adjuvant systemic treatments (targeting specific molecular pathways), the high percentage of survival from breast cancer led CVD to become the first cause of death among survivors. Therefore, it is mandatory to adopt cardioprotective strategies to minimize CV side effects and CVD in general in breast cancer patients. Cancer therapeutics-related cardiac dysfunction (CTRCD) is a common group of side effects of chemotherapeutics widely employed in breast cancer (e.g., anthracycline and human epidermal growth factor receptor 2 inhibitors). The aim of the present manuscript is to propose a pragmatic multidisciplinary stepwise approach for prevention, early detection, and treatment of cardiotoxicity in patients with breast cancer.

8 March 2019 in Stem Cells and Development
Verified
Journal Article
Closed access
FQFrancesca Querques
Francesca Querques
ADAnna D'Agostino
Anna D'Agostino
CCCarmine Cozzolino
Carmine Cozzolino
LCLuca Cozzuto
Luca Cozzuto
BLBarbara Lombardo
Barbara Lombardo
LPLucio Pastore
Lucio Pastore
Osteogenic differentiation is a complex and still poorly understood biological process regulated by intrinsic cellular signals and extrinsic microenvironmental cues. Following appropriate stimuli, mesenchymal stem cells (MSCs) differentiate into osteoblasts through a tightly regulated multistep process driven by several transcription factors and characterized by the expression of a number of bone-specific proteins. In this study, we describe a novel transcription factor that we named osteoblast inducer (ObI)-1, involved in MSC differentiation toward the osteogenic lineage. ObI-1 encodes for a nuclear protein subjected to proteasomal degradation and expressed during osteoblast differentiation both in a murine multipotent mesenchymal cell line (W20-17) and in primary murine MSCs. RNA interference-mediated knockdown of ObI-1 expression significantly impairs osteoblast differentiation and matrix mineralization with reduced expression of the osteogenic markers, Runt-related transcription factor 2 (Runx2) and osteopontin. Conversely, ObI-1 overexpression enhances osteogenic differentiation and bone-specific markers expression. ObI-1 stimulates bone morphogenetic protein (BMP)-4 expression and the consequent activation of the Smad pathway; treatment with a BMP receptor type I antagonist completely abolishes ObI-1-mediated stimulation of osteogenic differentiation. Collectively, our findings suggest that ObI-1 modulates osteogenic differentiation, at least in part, through the BMP signaling pathway, increasing Runx2 activation and leading to osteoblast commitment and maturation.